Digital pathology is a dynamic & image-based environment that enables the gathering, managing, & interpreting of pathology information generated from a digitized glass slide. With the rise in its healthcare applications, such as primary & intraoperative diagnosis, medical student & resident training, diagnostic consultation, clinical research, & tumor boards, the Digital Pathology Market has witnessed considerable expansion in recent years.
Moreover, the surging global prevalence of oncology diseases like breast & testicular cancers, multiple myeloma, etc., has led various industry players to invest in new product developments in the field of pathology. These efforts have been well-supported by various governments worldwide, due to which the digital pathology industry has experienced an uptick in growth historically.
|Study Period||Historical Data: 2017-20|
|Base Year: 2021|
|Forecast Period: 2022-27|
|Regions Covered||North America: USA, Canada, Mexico|
|Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe|
|Asia-Pacific: China, India, Japan, South Korea, Australia, Rest of Asia - Pacifc|
|South America: Brazil, Argentina, Rest of South America|
|Middle East & Africa: UAE, Saudi Arabia, South Africa, Turkey, Rest of Middle East & Africa|
|Key Companies Profiled||3Dhistech Ltd., Apollo Enterprise Imaging Corp, Aurora Interactive Ltd., Koninklijke Philips, Corista Llc, Glencoe Software, Inc., Definiens Ag, F. Hoffmann-La Roche Ltd., Digipath Inc., Huron Technologies International Inc., Indica Labs Inc., Leica Biosystem Inc., Leica Microsystems Gmbh, Ligolab Llc, Mikroscan Technologies Inc. and others|
|Unit Denominations||USD Million/Billion|
The Global Digital Pathology Market is anticipated to grow at a CAGR of around 14% during the forecast period, i.e., 2022-27. The growth of the market attributes primarily to the mounting adoption of digital pathology in medical institutions for disease diagnosis as well as in medical colleges for training-based purposes.
Nowadays, the demand for digital pathology solutions has considerably grown due to the rising number of cases for both Communicable & Non-Communicable diseases (NCDs). In 2021, NCDs accounted for 71% of all global deaths, with more than 15 million people aged between 30-69 years dying from NCDs each year, of which 85% of these premature deaths occur in middle & low-income countries.
Due to a significantly high number of medical cases, healthcare facilities have started adopting digital technologies, which has resulted in the growing demand for digital pathology as one of the key solutions for expediting diagnosis-based operations. Moreover, several major medical colleges & hospitals have adopted digital pathology solutions, which, in turn, has encouraged other medical institutions to adopt similar practices in their respective countries. For instance:
· In 2021, the UK-based Nottingham University Hospitals NHS Trust (NUH) stated that it would deploy Indica Labs' HALO AP digital pathology software in order to manage & view scanned slides for primary diagnosis, secondary consultations, tumor boards, remote reporting, & multi-disciplinary team meetings.
· According to the WHO, as of 2021, a total number of NCD-related deaths occurred from Cardiovascular diseases (17.9 million), cancer (9.3 million), respiratory diseases (4.1 million), & diabetes (1.5 million).
The trend shows a high number of NCD cases, which shall surge further with the increasing population & usage of tobacco, coupled with sedentary lifestyles. It, in turn, would provide more opportunities for the adoption of digital pathology solutions in the healthcare sector for easy & timely diagnosis of diseases